[Impact of systematic vaccination with the antimeningococcal C conjugated vaccine in a health area in Andalusia]
- PMID: 16457057
- DOI: 10.1590/s1135-57272005000600005
[Impact of systematic vaccination with the antimeningococcal C conjugated vaccine in a health area in Andalusia]
Abstract
Background: A retrospective longitudinal study of population incidence was made to assess the effectiveness of meningococcal serogroup C conjugate vaccine, after its mass introduction in children in the geographic area of a health district, measuring its population impact, and we have studied the state of the meningococcal disease.
Methods: Vaccine coverage in children born between 1991 and 2001, and rates of incidence in declared cases of meningococcal disease in seven epidemiological seasons (1997/98 to 2003/04) were calculated. The impact of vaccination against serogroup C meningitis was assessed comparing the average annual rates of previous and later seasons to the vaccination campaigns in population younger and older than 10, using the Fisher exact test.
Results: In all the study period, 109 cases of meningococcal disease were declared, of which 50 were of serogroup C meningococcal disease. Starting from 2000/2001 season the incidence of serogroup C disease decreased in the population below 10. In this age group, the annual average rate of post-vaccine seasons decreases in respect to pre-vaccine (from 8.2 to 2.0 per 100,000 inhabitants) showing a statistically significant difference. In the population above 10 years, this incidence reduction was not observed. In the study period, no case of vaccine failure was declared.
Conclusions: The absence of vaccine failure and the impact observed on the incidence of serogroup C meningococcal disease in children under 10 suggests the effectiveness of this new conjugate vaccine, together with suitable vaccination conditions (vaccination schedule, high catch-up, etc.) which are developing in our health district.
Similar articles
-
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.Pediatr Infect Dis J. 2006 Jan;25(1):79-80. doi: 10.1097/01.inf.0000195594.41449.c6. Pediatr Infect Dis J. 2006. PMID: 16395110
-
[Meningococcal C conjugate vaccine: Impact of a vaccination program and long-term effectiveness in Navarra, Spain, 2000-2014].Enferm Infecc Microbiol Clin. 2016 Dec;34(10):639-644. doi: 10.1016/j.eimc.2015.11.020. Epub 2016 Jan 15. Enferm Infecc Microbiol Clin. 2016. PMID: 26778101 Spanish.
-
Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.Vaccine. 2014 May 7;32(22):2604-9. doi: 10.1016/j.vaccine.2014.03.010. Epub 2014 Mar 21. Vaccine. 2014. PMID: 24662700
-
Global practices of meningococcal vaccine use and impact on invasive disease.Pathog Glob Health. 2014 Jan;108(1):11-20. doi: 10.1179/2047773214Y.0000000126. Pathog Glob Health. 2014. PMID: 24548156 Free PMC article. Review.
-
Evolving meningococcal immunization strategies.Expert Rev Vaccines. 2015 Apr;14(4):505-17. doi: 10.1586/14760584.2015.979799. Epub 2014 Dec 10. Expert Rev Vaccines. 2015. PMID: 25494168 Review.
Cited by
-
Impact and effectiveness of meningococcal vaccines: a review.Rev Panam Salud Publica. 2017 Dec 20;41:e158. doi: 10.26633/RPSP.2017.158. eCollection 2017. Rev Panam Salud Publica. 2017. PMID: 31391840 Free PMC article.
-
Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.BMC Public Health. 2020 Dec 9;20(1):1890. doi: 10.1186/s12889-020-09946-1. BMC Public Health. 2020. PMID: 33298015 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical